| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Hina Khan, Fareeha Khalid Ghori, Uzma Ghani, Aneela Javed, Saadia Zahi. Cannabinoid and endocannabinoid system: a promising therapeutic intervention for multiple sclerosis. Molecular biology reports. 2022-02-19. PMID:35182322. |
the cannabinoid receptors 1 (cb1) and 2 (cb2) of ecs are the main ones in focus for therapeutic intervention of ms. |
2022-02-19 |
2023-08-13 |
Not clear |
| Rosaria Greco, Chiara Demartini, Anna Maria Zanaboni, Miriam Francavilla, Roberto De Icco, Lara Ahmad, Cristina Tassorell. The endocannabinoid system and related lipids as potential targets for the treatment of migraine-related pain. Headache. 2022-02-18. PMID:35179780. |
a major advance in cannabinoid research has been the discovery of the endocannabinoid system (ecs), which consists of receptors cb1 and cb2; their endogenous ligands, such as n-arachidonoylethanolamine; and the enzymes that catalyze endocannabinoid biosynthesis or degradation. |
2022-02-18 |
2023-08-13 |
Not clear |
| Si-Jing Hu, Gang Cheng, Hao Zhou, Qi Zhang, Quan-Long Zhang, Yang Wang, Yi Shen, Chen-Xia Lian, Xue-Qin Ma, Qiao-Yan Zhang, Lu-Ping Qi. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects. Molecules (Basel, Switzerland). vol 27. issue 3. 2022-02-15. PMID:35163968. |
identification of novel cannabinoid cb2 receptor agonists from botanical compounds and preliminary evaluation of their anti-osteoporotic effects. |
2022-02-15 |
2023-08-13 |
Not clear |
| Si-Jing Hu, Gang Cheng, Hao Zhou, Qi Zhang, Quan-Long Zhang, Yang Wang, Yi Shen, Chen-Xia Lian, Xue-Qin Ma, Qiao-Yan Zhang, Lu-Ping Qi. Identification of Novel Cannabinoid CB2 Receptor Agonists from Botanical Compounds and Preliminary Evaluation of Their Anti-Osteoporotic Effects. Molecules (Basel, Switzerland). vol 27. issue 3. 2022-02-15. PMID:35163968. |
as cannabinoid cb2 receptors (cb2r) possess various pharmacological effects-including anti-epilepsy, analgesia, anti-inflammation, anti-fibrosis, and regulation of bone metabolism-without the psychoactive side effects induced by cannabinoid cb1r activation, they have become the focus of research and development of new target drugs in recent years. |
2022-02-15 |
2023-08-13 |
Not clear |
| Hae-Won Son, Declan William Al. Endocannabinoid Receptor Expression in Early Zebrafish Development. Developmental neuroscience. 2022-02-15. PMID:35168237. |
this study combines reverse-transcriptase pcr with in situ hybridizations to compile a timeline of the developmental expression of six key cannabinoid receptors; cb1, cb2, trpv1, trpa1a, trpa1b, and gpr55 in zebrafish embryos, starting from as early as 6 hours post fertilization (hpf) until 3 days post fertilization. |
2022-02-15 |
2023-08-13 |
human |
| Marcia G Honig, Nobel A Del Mar, Desmond L Henderson, Dylan O'Neal, Meghna Yammanur, Rachel Cox, Chunyan Li, Aaron M Perry, Bob M Moore, Anton Reine. Raloxifene, a cannabinoid type-2 receptor inverse agonist, mitigates visual deficits and pathology and modulates microglia after ocular blast. Experimental eye research. 2022-02-10. PMID:35143834. |
cannabinoid type-2 receptor (cb2) inverse agonists specifically target activated microglia, biasing them away from the harmful pro-inflammatory m1 state toward the helpful reparative m2 state. |
2022-02-10 |
2023-08-13 |
mouse |
| Melissa A Ribeiro, Rafael P Aguiar, Franciele F Scarante, Eduardo J Fusse, Rubia M W de Oliveira, Francisco S Guimaraes, Alline C Campo. Spontaneous Activity of CB Frontiers in pharmacology. vol 12. 2022-02-07. PMID:35126139. |
endocannabinoid system, which comprises cb2 receptors, has been associated with the chronic effects of these drugs, especially in stressed mice. |
2022-02-07 |
2023-08-13 |
mouse |
| Valerie L Joers, Hannah Staley, Maclean Bassett, Brenda D Moore, Malu Gamez Tanse. The role of cannabinoid receptor 2 in microglial clearance of human tau. Alzheimer's & dementia : the journal of the Alzheimer's Association. vol 17 Suppl 3. 2022-02-03. PMID:35109165. |
cannabinoid type 2 receptors (cb2) are highly expressed in immune cells and upregulated in activated microglia under conditions of neurologic disease, such as ad. |
2022-02-03 |
2023-08-13 |
human |
| Hagar Bauminger, Hiba Zaidan, Irit Akirav, Inna Gaisler-Salomo. Anandamide Hydrolysis Inhibition Reverses the Long-Term Behavioral and Gene Expression Alterations Induced by MK-801 in Male Rats: Differential CB1 and CB2 Receptor-Mediated Effects. Schizophrenia bulletin. 2022-01-29. PMID:35092675. |
prevention of behavioral and molecular abnormalities by late-adolescence urb597 via cb1 and cb2 receptors suggests that endocannabinoid stimulation may have therapeutic potential in addressing treatment-resistant symptoms. |
2022-01-29 |
2023-08-13 |
rat |
| Berhanu Geresu Kibret, Hiroki Ishiguro, Yasue Horiuchi, Emmanuel S Onaiv. New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders. International journal of molecular sciences. vol 23. issue 2. 2022-01-21. PMID:35055161. |
new insights and potential therapeutic targeting of cb2 cannabinoid receptors in cns disorders. |
2022-01-21 |
2023-08-13 |
human |
| Berhanu Geresu Kibret, Hiroki Ishiguro, Yasue Horiuchi, Emmanuel S Onaiv. New Insights and Potential Therapeutic Targeting of CB2 Cannabinoid Receptors in CNS Disorders. International journal of molecular sciences. vol 23. issue 2. 2022-01-21. PMID:35055161. |
together, the ecs and the expanded endocannabinoidome (ecbome) are composed of genes coding for cb1 and cb2 cannabinoid receptors (cb1r, cb2r), endocannabinoids (ecbs), and the metabolic enzyme machinery for their synthesis and catabolism. |
2022-01-21 |
2023-08-13 |
human |
| Jiayi Yuan, Chen Jiang, Junmei Wang, Chih-Jung Chen, Yixuan Hao, Guangyi Zhao, Zhiwei Feng, Xiang-Qun Xi. In Silico Prediction and Validation of CB2 Allosteric Binding Sites to Aid the Design of Allosteric Modulators. Molecules (Basel, Switzerland). vol 27. issue 2. 2022-01-21. PMID:35056767. |
although the 3d structures of active and inactive cannabinoid receptors type 2 (cb2) are available, neither the x-ray crystal nor the cryo-em structure of cb2-orthosteric ligand-modulator has been resolved, prohibiting the drug discovery and development of cb2 allosteric modulators (ams). |
2022-01-21 |
2023-08-13 |
Not clear |
| Yongmin Liu, Min Jia, Caihua Wu, Hong Zhang, Chao Chen, Wenqiang Ge, Kexing Wan, Yuye Lan, Shiya Liu, Yuanheng Li, Mengyue Fang, Jiexi He, Hui-Lin Pan, Jun-Qiang Si, Man L. Transcriptomic Profiling in Mice With CB1 receptor Deletion in Primary Sensory Neurons Suggests New Analgesic Targets for Neuropathic Pain. Frontiers in pharmacology. vol 12. 2022-01-20. PMID:35046811. |
type 1 and type 2 cannabinoid receptors (cb1 and cb2, respectively) mediate cannabinoid-induced analgesia. |
2022-01-20 |
2023-08-13 |
mouse |
| Xiaoyan Lin, Zhili Xu, Lawrence Carey, Julian Romero, Alexandros Makriyannis, Cecilia J Hillard, Elizabeth Ruggiero, Marilyn Dockum, George Houk, Ken Mackie, Phillip J Albrecht, Frank L Rice, Andrea G Hohman. A peripheral CB2 cannabinoid receptor mechanism suppresses chemotherapy-induced peripheral neuropathy: evidence from a CB2 reporter mouse. Pain. 2022-01-10. PMID:35001054. |
cb2 cannabinoid receptors (cb2) are a promising therapeutic target that lacks unwanted side effects of cb1 activation. |
2022-01-10 |
2023-08-13 |
mouse |
| Szymon Hryhorowicz, Marta Kaczmarek-Ryś, Aleksandra Zielińska, Rodney J Scott, Ryszard Słomski, Andrzej Pławsk. Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review. Frontiers in immunology. vol 12. 2022-01-10. PMID:35003109. |
it consists of cannabinoid receptors (cb1 and cb2), transporters for cellular uptake of endocannabinoid ligands, endogenous bioactive lipids (anandamide and 2-arachidonoylglycerol), and the enzymes responsible for their synthesis and degradation (fatty acid amide hydrolase and monoacylglycerol lipase), the manipulation of which through agonists and antagonists of the system, shows a potential therapeutic role for ecs in inflammatory bowel disease. |
2022-01-10 |
2023-08-13 |
Not clear |
| Shrouq I Farah, Samantha Hilston, Ngan Tran, Nikolai Zvonok, Alexandros Makriyanni. 1-, 2- and 3-AG as substrates of the endocannabinoid enzymes and endogenous ligands of the cannabinoid receptor 1. Biochemical and biophysical research communications. vol 591. 2022-01-07. PMID:34995983. |
2-arachidonoylglycerol (2-ag) is the most potent and abundant endocannabinoid that acts as a full agonist at the cannabinoid 1 (cb1) and 2 (cb2) receptors. |
2022-01-07 |
2023-08-13 |
Not clear |
| Hayley Worth, Daniel O'Hara, Neeru Agarwal, David Collister, Frank Brennan, Brendan Smyt. Cannabinoids for Symptom Management in Patients with Kidney Failure. Clinical journal of the American Society of Nephrology : CJASN. 2022-01-06. PMID:34987023. |
cannabinoid receptors, cb1 and cb2, are widely expressed in the body, including within the nervous and immune systems, and exogenous cannabinoids can have anxiolytic, anti-emetic, analgesic and anti-inflammatory effects. |
2022-01-06 |
2023-08-13 |
Not clear |
| Subramaniam Jayanthi, Ritvik Peesapati, Michael T McCoy, Bruce Ladenheim, Jean Lud Cade. Footshock-Induced Abstinence from Compulsive Methamphetamine Self-administration in Rat Model Is Accompanied by Increased Hippocampal Expression of Cannabinoid Receptors (CB1 and CB2). Molecular neurobiology. 2022-01-03. PMID:34978045. |
footshock-induced abstinence from compulsive methamphetamine self-administration in rat model is accompanied by increased hippocampal expression of cannabinoid receptors (cb1 and cb2). |
2022-01-03 |
2023-08-13 |
rat |
| Yan Shi, Mengxi Liu, Xiangjun Li, Niusheng Xu, Shuai Yuan, Zhiguo Yu, Ping Xiang, Hejian W. Simultaneous screening of 239 synthetic cannabinoids and metabolites in blood and urine samples using liquid chromatography-high resolution mass spectrometry. Journal of chromatography. A. vol 1663. 2022-01-02. PMID:34974369. |
synthetic cannabinoids (scs) are new psychoactive substances that function as endocannabinoid cb1 and cb2 receptor agonists. |
2022-01-02 |
2023-08-13 |
Not clear |
| Takashi Tanikawa, Masashi Kitamura, Yasuhiro Hayashi, Takami Yokogawa, Yutaka Inou. Curcumae Longae Rhizoma and Saussureae Radix Inhibit Nitric Oxide Production and Cannabinoid Receptor 2 Down-regulation. In vivo (Athens, Greece). vol 36. issue 1. 2022-01-01. PMID:34972719. |
the cannabinoid 2 (cb2) receptor is an important regulator of immunoinflammatory responses. |
2022-01-01 |
2023-08-13 |
Not clear |